What Gives? Seems to be seeing some spectacular rise here without much in terms of RNS. Just previous announcements hammering home?
18p paid Gradually gaining momentum here !TP
Re: Further Medicare coverage Now lets get that US salesforce working - no excuses now!
Further Medicare coverage TRX now have 9 out of 11 Medicare areas I the US, for Dermapure.Huge potential for increased sales this year.TP
RNS 3 Feb Interesting piece, putting TRX out there in the US.TP
Re: Nice Trade Looking at the smaller trades around the big one I'd go for the new motor scenario :- ((. (Nice car though!)TP
Nice Trade At 15:57, 1,000,000 shares £153,000. Either a good buy or someone wants a new motor.YB
Re: TRX in to the EU via German Tissue B... I think the potential issue is that in the report it alludes to a fund raies in future years, also was Eurpope not a lesser market for products!
Re: TRX in to the EU via German Tissue B... Agreed TP.Looking at the 3 year graph, the SP bounced off 31p in early 2014, 2 days ago the very weighty Hardman Report was talking of an NPV of 41p and yesterday the German Tissue Bank taking the technology into the EU, the SP should be heading for 50p rather than loitering around at 16p. I would have thought at the very least,, a 3 fold increase. Never mind, I'm in and holding. YB
Re: TRX in to the EU via German Tissue Bank Excellent news, a way into Europe.Surprised noone's dipped their toe in this morning on the strength of it.
TRX in to the EU via German Tissue Bank Great News.Tissue Regenix Group plcJoint Venture Agreement York, 26 January 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group" announces first step towards the commercialisation of human dCELL® heart valves and DermaPure® in the EU through a Joint Venture Agreement with German tissue bank.Highlights· Joint Venture Agreement ("JVA" entered into with GTM-V to form GBM-V gGmbH ("GBM-V", a tissue bank based in Rostock, Germany· Non-exclusive licences granted to GBM-V for human dCELL® heart valves & DermaPure® covering the EU· First licence granted for dCELL® heart valves· Regulatory submissions to German authorities being prepared by GBM-V· First products targeted to be launched in 2017 subject to regulatory approval· The Group anticipates replicating this business model in other countries, with initial discussions already heldYB
Re: NPV 42p....Hardman Report 8237M issued at 0700 25/1/16TP
Re: NPV 42p....Hardman Report Which rns please i can t see one anywhere published today?
NPV 42p....Hardman Report Today's RNS. More good news !TP
Report As per Edisons - linkwww.edisoninvestmentresearch.com/?ACT=18&ID=15135